Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
How would you approach the treatment of a patient with contraindications to amivantamab?